相关实验视频
Updated: Jun 23, 2025

Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
开发具有抗血栓性质的新型模性NADPH氧化酶抑制剂
Elisabetta Scalia1, Antony Chirco1, Lorenzo Calugi1
1Department of Chemistry "Ugo Schiff", University of Florence, Via della Lastruccia 13, 50019, Sesto Fiorentino, Florence, Italy.
针对NOX1 (NADPH氧化酶1) 的合成被开发来抑制反应性氧物种 (ROS) 生产. 修改后的NOXA1显示出更好的效能和稳定性,具有作为抗血栓性药物的潜力.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- NADPH氧化酶1 (NOX1) 参与ROS的产生,有助于血栓形成过程.
- NOX1衍生的超氧化 (O2⋅−) 形成是治疗干预的关键目标.
- 已知NOXA1亚单元的活性表位抑制NOX1活动.
研究的目的:
- 设计和合成基于NOXA1表位基的新型皮相仿NOX1抑制剂.
- 为了提高NOX1抑制剂的功效和血稳定性.
- 为了确定有前途的药物候选人,用于抗血栓治疗.
主要方法:
- 酸-酸杂交物和聚合的设计和合成.
- 对NOX1衍生的O2⋅−形成的抑制活性的评估.
- 在血中评估的稳定性.
主要成果:
- 类-类混合体GS2证明了提高了疗效和功效.
- Stapled AC5 和它的前体表现出增强的血稳定性.
- 最小的结构修改显著影响了功效和稳定性.
结论:
- 改性NOXA1是一种可行的策略,用于开发强效和稳定的NOX1抑制剂.
- 开发的化合物显示出作为新型抗血栓剂的潜力.
- 结构优化是实现NOX1抑制所需的治疗配置的关键.
更多相关视频
07:13Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
Published on: May 24, 2024
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antihypertensive Drugs: Vasodilators
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...